Selected research
Industry Research
Dementia Drugs Industry Research Report 2026
Market perspective
The global Dementia Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Dementia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Dementia Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Dementia Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Dementia Drugs include Janssen Pharmaceuticals, Inc, Eisai, Inc, Teva Pharmaceuticals Industries, Sanofi S.A, Johnson and Johnson, Novartis AG, Eli Lilly and Company, Pfizer Inc and Abbvie Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Dementia Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dementia Drugs Market by Company
Janssen Pharmaceuticals, Inc
Eisai, Inc
Teva Pharmaceuticals Industries
Sanofi S.A
Johnson and Johnson
Novartis AG
Eli Lilly and Company
Pfizer Inc
Abbvie Inc
AstraZeneca GmbH
Zydus Cadila
Valeant Pharmaceutical International
Merck & Co., Inc
Forest Laboratories, Inc
F. Hoffmann-La Roche
Biogen Pharmaceuticals
Aurobindo Pharma
Apotex inc.
Dementia Drugs Segment by Type
Glutamate Inhibitors
Cholinesterase Inhibitors
MAO Inhibitors
Dementia Drugs Segment by Application
Hospital Pharmacies
Retail Pharmacies
Others
Dementia Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dementia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dementia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dementia Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Dementia Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Dementia Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Dementia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Glutamate Inhibitors
- Cholinesterase Inhibitors
- MAO Inhibitors
Applications
- Hospital Pharmacies
- Retail Pharmacies
- Others
Companies covered
- Janssen Pharmaceuticals, Inc
- Eisai, Inc
- Teva Pharmaceuticals Industries
- Sanofi S.A
- Johnson and Johnson
- Novartis AG
- Eli Lilly and Company
- Pfizer Inc
- Abbvie Inc
- AstraZeneca GmbH
- Zydus Cadila
- Valeant Pharmaceutical International
- Merck & Co., Inc
- Forest Laboratories, Inc
- F. Hoffmann-La Roche
- Biogen Pharmaceuticals
- Aurobindo Pharma
- Apotex inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Dementia Drugs Market Size (2021-2032)
- 2.2.2 Global Dementia Drugs Sales (2021-2032)
- 2.2.3 Global Dementia Drugs Market Average Price (2021-2032)
- 2.3 Dementia Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Glutamate Inhibitors
- 2.3.3 Cholinesterase Inhibitors
- 2.3.4 MAO Inhibitors
- 2.4 Dementia Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Retail Pharmacies
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Dementia Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Dementia Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Dementia Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Dementia Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Dementia Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Dementia Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Dementia Drugs, Product Type & Application
- 3.8 Global Manufacturers of Dementia Drugs, Established Date
- 3.9 Global Dementia Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Janssen Pharmaceuticals, Inc
- 4.1.1 Janssen Pharmaceuticals, Inc Company Information
- 4.1.2 Janssen Pharmaceuticals, Inc Business Overview
- 4.1.3 Janssen Pharmaceuticals, Inc Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Janssen Pharmaceuticals, Inc Dementia Drugs Product Portfolio
- 4.1.5 Janssen Pharmaceuticals, Inc Recent Developments
- 4.2 Eisai, Inc
- 4.2.1 Eisai, Inc Company Information
- 4.2.2 Eisai, Inc Business Overview
- 4.2.3 Eisai, Inc Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eisai, Inc Dementia Drugs Product Portfolio
- 4.2.5 Eisai, Inc Recent Developments
- 4.3 Teva Pharmaceuticals Industries
- 4.3.1 Teva Pharmaceuticals Industries Company Information
- 4.3.2 Teva Pharmaceuticals Industries Business Overview
- 4.3.3 Teva Pharmaceuticals Industries Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Teva Pharmaceuticals Industries Dementia Drugs Product Portfolio
- 4.3.5 Teva Pharmaceuticals Industries Recent Developments
- 4.4 Sanofi S.A
- 4.4.1 Sanofi S.A Company Information
- 4.4.2 Sanofi S.A Business Overview
- 4.4.3 Sanofi S.A Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sanofi S.A Dementia Drugs Product Portfolio
- 4.4.5 Sanofi S.A Recent Developments
- 4.5 Johnson and Johnson
- 4.5.1 Johnson and Johnson Company Information
- 4.5.2 Johnson and Johnson Business Overview
- 4.5.3 Johnson and Johnson Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Johnson and Johnson Dementia Drugs Product Portfolio
- 4.5.5 Johnson and Johnson Recent Developments
- 4.6 Novartis AG
- 4.6.1 Novartis AG Company Information
- 4.6.2 Novartis AG Business Overview
- 4.6.3 Novartis AG Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novartis AG Dementia Drugs Product Portfolio
- 4.6.5 Novartis AG Recent Developments
- 4.7 Eli Lilly and Company
- 4.7.1 Eli Lilly and Company Company Information
- 4.7.2 Eli Lilly and Company Business Overview
- 4.7.3 Eli Lilly and Company Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Eli Lilly and Company Dementia Drugs Product Portfolio
- 4.7.5 Eli Lilly and Company Recent Developments
- 4.8 Pfizer Inc
- 4.8.1 Pfizer Inc Company Information
- 4.8.2 Pfizer Inc Business Overview
- 4.8.3 Pfizer Inc Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pfizer Inc Dementia Drugs Product Portfolio
- 4.8.5 Pfizer Inc Recent Developments
- 4.9 Abbvie Inc
- 4.9.1 Abbvie Inc Company Information
- 4.9.2 Abbvie Inc Business Overview
- 4.9.3 Abbvie Inc Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Abbvie Inc Dementia Drugs Product Portfolio
- 4.9.5 Abbvie Inc Recent Developments
- 4.10 AstraZeneca GmbH
- 4.10.1 AstraZeneca GmbH Company Information
- 4.10.2 AstraZeneca GmbH Business Overview
- 4.10.3 AstraZeneca GmbH Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AstraZeneca GmbH Dementia Drugs Product Portfolio
- 4.10.5 AstraZeneca GmbH Recent Developments
- 4.11 Zydus Cadila
- 4.11.1 Zydus Cadila Company Information
- 4.11.2 Zydus Cadila Business Overview
- 4.11.3 Zydus Cadila Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Zydus Cadila Dementia Drugs Product Portfolio
- 4.11.5 Zydus Cadila Recent Developments
- 4.12 Valeant Pharmaceutical International
- 4.12.1 Valeant Pharmaceutical International Company Information
- 4.12.2 Valeant Pharmaceutical International Business Overview
- 4.12.3 Valeant Pharmaceutical International Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Valeant Pharmaceutical International Dementia Drugs Product Portfolio
- 4.12.5 Valeant Pharmaceutical International Recent Developments
- 4.13 Merck & Co., Inc
- 4.13.1 Merck & Co., Inc Company Information
- 4.13.2 Merck & Co., Inc Business Overview
- 4.13.3 Merck & Co., Inc Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Merck & Co., Inc Dementia Drugs Product Portfolio
- 4.13.5 Merck & Co., Inc Recent Developments
- 4.14 Forest Laboratories, Inc
- 4.14.1 Forest Laboratories, Inc Company Information
- 4.14.2 Forest Laboratories, Inc Business Overview
- 4.14.3 Forest Laboratories, Inc Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Forest Laboratories, Inc Dementia Drugs Product Portfolio
- 4.14.5 Forest Laboratories, Inc Recent Developments
- 4.15 F. Hoffmann-La Roche
- 4.15.1 F. Hoffmann-La Roche Company Information
- 4.15.2 F. Hoffmann-La Roche Business Overview
- 4.15.3 F. Hoffmann-La Roche Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 F. Hoffmann-La Roche Dementia Drugs Product Portfolio
- 4.15.5 F. Hoffmann-La Roche Recent Developments
- 4.16 Biogen Pharmaceuticals
- 4.16.1 Biogen Pharmaceuticals Company Information
- 4.16.2 Biogen Pharmaceuticals Business Overview
- 4.16.3 Biogen Pharmaceuticals Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Biogen Pharmaceuticals Dementia Drugs Product Portfolio
- 4.16.5 Biogen Pharmaceuticals Recent Developments
- 4.17 Aurobindo Pharma
- 4.17.1 Aurobindo Pharma Company Information
- 4.17.2 Aurobindo Pharma Business Overview
- 4.17.3 Aurobindo Pharma Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Aurobindo Pharma Dementia Drugs Product Portfolio
- 4.17.5 Aurobindo Pharma Recent Developments
- 4.18 Apotex inc.
- 4.18.1 Apotex inc. Company Information
- 4.18.2 Apotex inc. Business Overview
- 4.18.3 Apotex inc. Dementia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Apotex inc. Dementia Drugs Product Portfolio
- 4.18.5 Apotex inc. Recent Developments
5 Global Dementia Drugs Market Scenario by Region
- 5.1 Global Dementia Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Dementia Drugs Sales by Region: 2021-2032
- 5.2.1 Global Dementia Drugs Sales by Region: 2021-2026
- 5.2.2 Global Dementia Drugs Sales by Region: 2027-2032
- 5.3 Global Dementia Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Dementia Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Dementia Drugs Revenue by Region: 2027-2032
- 5.4 North America Dementia Drugs Market Facts & Figures by Country
- 5.4.1 North America Dementia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Dementia Drugs Sales by Country (2021-2032)
- 5.4.3 North America Dementia Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Dementia Drugs Market Facts & Figures by Country
- 5.5.1 Europe Dementia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Dementia Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Dementia Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Dementia Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Dementia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Dementia Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Dementia Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Dementia Drugs Market Facts & Figures by Country
- 5.7.1 South America Dementia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Dementia Drugs Sales by Country (2021-2032)
- 5.7.3 South America Dementia Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Dementia Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Dementia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Dementia Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Dementia Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Dementia Drugs Sales by Type (2021-2032)
- 6.1.1 Global Dementia Drugs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Dementia Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Dementia Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Dementia Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Dementia Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Dementia Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Dementia Drugs Sales by Application (2021-2032)
- 7.1.1 Global Dementia Drugs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Dementia Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Dementia Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Dementia Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Dementia Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Dementia Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Dementia Drugs Value Chain Analysis
- 8.1.1 Dementia Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Dementia Drugs Production Mode & Process
- 8.2 Dementia Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Dementia Drugs Distributors
- 8.2.3 Dementia Drugs Customers
9 Global Dementia Drugs Analyzing Market Dynamics
- 9.1 Dementia Drugs Industry Trends
- 9.2 Dementia Drugs Industry Drivers
- 9.3 Dementia Drugs Industry Opportunities and Challenges
- 9.4 Dementia Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst